Veracyte Q1 2021 Earnings Report
Key Takeaways
Veracyte announced its Q1 2021 financial results, reporting a total revenue of $36.7 million, an 18% increase compared to the previous year. The company's genomic testing volume grew by 11% to 14,437 tests. Veracyte also completed the acquisition of Decipher Biosciences, expanding its reach into urologic cancer testing.
Total revenue increased by 18% to $36.7 million, including $3.8 million from urologic cancer testing.
Genomic testing volume increased by 11% to 14,437 tests, including 1,560 tests from Decipher Biosciences.
Gross margin was reported at 66%.
Completed the acquisition of Decipher Biosciences, expanding reach into 7 of the top 10 cancers in the U.S.
Veracyte
Veracyte
Veracyte Revenue by Segment
Forward Guidance
Veracyte is reiterating its previous 2021 annual total revenue guidance of approximately $190 million to $200 million, representing growth of approximately 65% over 2020 at the midpoint of the range.
Revenue & Expenses
Visualization of income flow from segment revenue to net income